top of page
Browse by category
Search
Antag begins trial of AT-7687, a GIPR antagonist designed to address key gaps in obesity treatment
Antag Therapeutics has initiated its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent...
FDA grants IND application for Antag Therapeutics’ AT-7687 molecule for obesity
The FDA has accepted Antag Therapeutics’ Investigational New Drug (IND) application for its lead molecule, AT-7687, for the treatment of...
Browse by tag
bottom of page